Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002007385 | SCV002232346 | pathogenic | not provided | 2021-04-30 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This sequence change creates a premature translational stop signal (p.Tyr264*) in the HSD3B2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 109 amino acid(s) of the HSD3B2 protein. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with HSD3B2-related conditions. This variant disrupts the C-terminus of the HSD3B2 protein. Other variant(s) that disrupt this region (p.Arg335*) have been determined to be pathogenic (PMID: 18252794, 31006099). This suggests that variants that disrupt this region of the protein are likely to be causative of disease. |
Fulgent Genetics, |
RCV005006306 | SCV005643031 | likely pathogenic | 3 beta-Hydroxysteroid dehydrogenase deficiency | 2024-02-26 | criteria provided, single submitter | clinical testing |